65
Participants
Start Date
November 1, 2012
Primary Completion Date
October 9, 2013
Study Completion Date
October 9, 2013
CC-220 0.03 mg
A single dose of CC-220 0.03 mg will be administered orally once a day.
CC-220 0.1 mg
A single dose of CC-220 0.1 mg will be administered orally once a day.
CC-220 0.3 mg
A single dose of CC-220 0.3 mg will be administered orally once a day.
CC-220 1 mg
A single dose of CC-220 1 mg will be administered orally once a day.
CC-220 2 mg
A single dose of CC-220 2 mg will be administered orally once a day.
Placebo
A single dose of placebo will be administered orally once a day.
CC-220
CC-220 4 mg will be administered orally once a day
CC-220
CC-220 6 mg will be administered orally once a day
CC-220
CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
Covance Clinical Research Unit, Madison
Lead Sponsor
Celgene
INDUSTRY